Market Place
Company
Upload your Marketing & Sales content on your company Virtual Booth, click HERE
X
Details:
New data show proportions of patients treated with TREMFYA (guselkumab) who achieved clinical-biomarker response ranged from 47.5-66.7 percent across dose groups in the Phase 2 GALAXI 1 study.
Lead Product(s): Guselkumab
Therapeutic Area: Gastroenterology Product Name: Tremfya
Highest Development Status: Phase II/ Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 24, 2022
Details:
Etrasimod is a next generation highly selective sphingosine 1-phosphate (S1P) receptor modulator discovered by Arena and designed for optimized pharmacology and engagement of S1P receptors 1, 4, and 5, which may lead to an improved efficacy and safety profile.
Lead Product(s): Etrasimod
Therapeutic Area: Gastroenterology Product Name: APD334
Highest Development Status: Phase II/ Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 19, 2021
Details:
Combined public entity to develop and commercialize next-generation immune therapies like CYTO-200, that address unmet needs in oncology, infectious disease, inflammation and auto-immune-mediated conditions.
Lead Product(s): CYTO-200
Therapeutic Area: Gastroenterology Product Name: CYTO-200
Highest Development Status: Phase II/ Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Cleveland Clinic
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Merger February 17, 2021
Details:
Patent provide claims covering “Clonidine and/or clonidine derivatives for use in the prevention and/or treatment of adverse side effects of chemotherapy”.
Lead Product(s): Clonidine
Therapeutic Area: Gastroenterology Product Name: Validive
Highest Development Status: Phase II/ Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 09, 2020
Details:
The EMA application is supported by data from the Phase 2b/3 SELECTION study, which showed a statistically significantly higher proportion of patients treated with once-daily filgotinib 200 mg achieved clinical remission at week 10 and maintained remission at week 58.
Lead Product(s): Filgotinib
Therapeutic Area: Gastroenterology Product Name: Jyseleca
Highest Development Status: Phase II/ Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 02, 2020
Details:
Merger to create a single public company focused on the development and commercialization of immunotherapies for oncology, infectious disease, inflammation and auto-immune mediated conditions. Portfolio includes investigational drug, CYTO-201, for COVID-19 infection.
Lead Product(s): Noroxymorphone analogs
Therapeutic Area: Gastroenterology Product Name: CYTO-201
Highest Development Status: Phase II/ Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Cleveland BioLabs
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Merger October 20, 2020
Details:
At 12 weeks, TREMFYA induced significantly greater improvements compared to placebo across key clinical and endoscopic outcome measures, with a safety profile consistent with approved indications.1 TREMFYA is not currently approved for the treatment of CD in the U.S.
Lead Product(s): Guselkumab
Therapeutic Area: Gastroenterology Product Name: Tremfya
Highest Development Status: Phase II/ Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 12, 2020
Details:
Filgotinib 200mg Achieved Endoscopic, Histologic and Six-Month Corticosteroid-Free Remission at Week 58 with a Consistent Safety Profile.
Lead Product(s): Filgotinib
Therapeutic Area: Gastroenterology Product Name: Jyseleca
Highest Development Status: Phase II/ Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 12, 2020
Details:
AstraZeneca and Allergan have terminated their previous license agreement and all rights to brazikumab have therefore now returned to AstraZeneca.
Lead Product(s): Brazikumab
Therapeutic Area: Gastroenterology Product Name: Undisclosed
Highest Development Status: Phase II/ Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: AstraZeneca
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Termination May 11, 2020
Details:
AstraZeneca will acquire brazikumab, in Phase 2b/3 development for Crohn's Disease and in Phase 2 development for ulcerative colitis, including global development and commercial rights.
Lead Product(s): Brazikumab
Therapeutic Area: Gastroenterology Product Name: Undisclosed
Highest Development Status: Phase II/ Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: AstraZeneca
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Divestment January 27, 2020
